Figure S1 from Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid Tumors

2026 Open access

Read full text
Authors: Jong Chul Park, David Berz, Manish R. Sharma, Jyoti Dhar Malhotra, Anthony W. Tolcher, Ralph J. Hauke, Justin Call, John Turner Hamm, Rachel E. Sanborn, Naomi Balzer Haas, Frank Yung-Chin Tsai, Douglas R. Adkins
+8 more D. Ross Camidge, Alexander I. Spira, Lane Senne, James L. Kalabus, Brianne O’Neill, Heather Kinkead, Josep Garcia, Erminia Massarelli
DOI: 10.1158/2767-9764.31387957
Cited by: 0

Abstract

Figure S1 shows that in vitro INBRX-105 blocks PD-1 binding of PD-L1, induces signaling downstream of 4-1BB in a PD-L1–dependent manner, and has greater binding affinity for PD-L1 vs 4-1BB

Fields of Study & Subjects

Cancer Immunotherapy and Biomarkers Monoclonal and Polyclonal Antibodies Research Immunotherapy and Immune Responses

Publication details

Publication date
23 February 2026
Language
EN